Interpretation of the BRIGHT-2 Trial

JAMA Oncology · Published 2026-07-30 · DOI 10.1001/jamaoncol.2026.2481

Authors (1)

Hongbo Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Citation

Li, H. (2026). Interpretation of the BRIGHT-2 Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2026.2481

Related articles

Considerations in Genomic Therapy Matching—Reply · JAMA Oncology · 2026 · Same journal
Survival Language · JAMA Oncology · 2026 · Same journal
A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0 · JAMA Oncology · 2026 · Same journal
Global Consensus on the Management of Primary Localized Chordoma · JAMA Oncology · 2026 · Same journal
Survival in the SONIA Trial—Reply · JAMA Oncology · 2026 · Same journal
When TNM Staging Is Not Sufficient · JAMA Oncology · 2026 · Same journal
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma · JAMA Oncology · 2026 · Same journal
Treatment Delays in Early Age–Onset Colorectal Cancer · JAMA Oncology · 2026 · Same journal
Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis—Reply · JAMA Oncology · 2026 · Same journal
Error in Open Access License · JAMA Oncology · 2026 · Same journal